Prevention and Management of Venous Thromboembolism in Pregnancy

American Journal of Medicine

Volumn 120, Issue 10 SUPPL. 2, 2007, Pages

  James, Andra H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Deep vein thrombosis; Pregnancy; Pulmonary embolism; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ARGATROBAN; DANAPAROID; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANGIOGRAPHY; ANTICOAGULATION; ARTICLE; BLEEDING; BONE DENSITY; CLINICAL FEATURE; CONGENITAL MALFORMATION; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; INTELLIGENCE QUOTIENT; LOW DRUG DOSE; LUNG EMBOLISM; LUNG FUNCTION TEST; LUNG VENTILATION; MATERNAL MORTALITY; NERVOUS SYSTEM INJURY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOLYSIS; PHLEBOGRAPHY; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SKIN MANIFESTATION; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SPONTANEOUS ABORTION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

ANTICOAGULANTS; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PRENATAL CARE; RISK FACTORS; VENOUS THROMBOSIS;

EID: 34748815594     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.08.011     Document Type: Article

References (119)

1. Dickson B. Venous thrombosis: on the history of Virchow's Triad. University of Toronto Medical Journal 81 (2004) 166-171
2. Gordon M. Maternal physiology in pregnancy. In: Gabbe S., Niebyl J., and Simpson J. (Eds). Normal and Problem Pregnancies. 4th ed. (2002), Churchill Livingstone, New York 63-92
3. Macklon N.S., Greer I.A., and Bowman A.W. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br J Obstet Gynaecol 104 (1997) 191-197
4. Whitty J., and Dombrowski M. Respiratory diseases in pregnancy. In: Gabbe S., Niebyl J., and Simpson J. (Eds). Normal and Problem Pregnancies. 4th ed. (2002), Churchill Livingstone, New York 1033-1064
5. Danilenko-Dixon D.R., Heit J.A., Silverstein M.D., et al. Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: a population-based, case-control study. Am J Obstet Gynecol 184 (2001) 104-110
6. Carr M.H., Towers C.V., Eastenson A.R., Pircon R.A., Iriye B.K., and Adashek J.A. Prolonged bedrest during pregnancy: does the risk of deep vein thrombosis warrant the use of routine heparin prophylaxis?. J Matern Fetal Med 6 (1997) 264-267
7. Kovacevich G.J., Gaich S.A., Lavin J.P., Hopkins M.P., Crane S.S., Stewart J., et al. The prevalence of thromboembolic events among women with extended bed rest prescribed as part of the treatment for premature labor or preterm premature rupture of membranes. Am J Obstet Gynecol 182 (2000) 1089-1092
8. Sikovanyecz J., Orvos H., Pal A., et al. Leiden mutation, bed rest and infection: simultaneous triggers for maternal deep-vein thrombosis and neonatal intracranial hemorrhage?. Fetal Diagn Ther 19 (2004) 275-277
9. Bremme K.A. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 16 (2003) 153-168
10. Medcalf R.L., and Stasinopoulos S.J. The undecided serpin: the ins and outs of plasminogen activator inhibitor type 2. FEBS J 272 (2005) 4858-4867
11. James A.H., Tapson V.F., and Goldhaber S.Z. Thrombosis during pregnancy and the postpartum period. Am J Obstet Gynecol 193 (2005) 216-219
12. Ray J.G., and Chan W.S. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv 54 (1999) 265-271
13. Postpartum Hemorrhage: Postpartum Hemorrhage Initiative, Office of Health, Infectious Diseases and Nutrition, Bureau for Global Health, US Agency for International Development. http://www.pphprevention.org/pph.php. Accessed September 3, 2007.
14. Chang J., Elam-Evans L.D., Berg C.J., et al. Pregnancy-related mortality surveillance-United States, 1991-1999. MMWR Surveill Summ 52 (2003) 1-8
15. Heit J.A., Kobbervig C.E., James A.H., Petterson T.M., Bailey K.R., and Melton III L.J. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 143 (2005) 697-706
16. James A.H., Jamison M.G., Brancazio L.R., and Myers E.R. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 194 (2006) 1311-1315
17. Bergqvist A., Bergqvist D., Lindhagen A., and Matzsch T. Late symptoms after pregnancy-related deep vein thrombosis. Br J Obstet Gynaecol 97 (1990) 338-341
18. Ulander V.M., Lehtola A., and Kaaja R. Long-term outcome of deep venous thrombosis during pregnancy treated with unfractionated heparin or low molecular weight heparin. Thrombosis Research 111 (2003) 239-242
19. Rosfors S., Noren A., Hjertberg R., Persson L., Lillthors K., and Torngren S. A 16-year haemodynamic follow-up of women with pregnancy-related medically treated iliofemoral deep venous thrombosis. Eur J Vasc Endovasc Surg 22 (2001) 448-455
20. Grandone E., Margaglione M., Colaizzo D., D'Andrea G., Cappucci G., Brancaccio V., et al. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol 179 (1998) 1324-1328
21. Gerhardt A., Scharf R.E., Beckmann M.W., et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 342 (2000) 374-380
22. McColl M.D., Ellison J., Reid F., Tait R.C., Walker I.D., and Greer I.A. Prothrombin 20210 G-- >A, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. BJOG 107 (2000) 565-569
23. Dilley A., Austin H., El-Jamil M., et al. Genetic factors associated with thrombosis in pregnancy in a United States population. Am J Obstet Gynecol 183 (2000) 1271-1277
24. Martinelli I., De Stefano V., Taioli E., Paciaroni K., Rossi E., and Mannucci P.M. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 87 (2002) 791-795
25. Rosendaal F.R., Koster T., Vandenbroucke J.P., and Reitsma P.H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85 (1995) 1504-1508
26. Robertson L., Wu O., Langhorne P., Twaddle S., Clark P., Lowe G.D., et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 132 (2006) 171-196
27. Pabinger I., Schneider B., and Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency: a cooperative, retrospective study. Arterioscler Thromb Vasc Biol 16 (1996) 742-748
28. Conard J., Horellou M.H., Van Dreden P., Lecompte T., and Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost 63 (1990) 319-320
29. Hellgren M., Tengborn L., and Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest 14 (1982) 127-141
30. Girling J., and de Swiet M. Inherited thrombophilia and pregnancy. Curr Opin Obstet Gynecol 10 (1998) 135-144
31. Krnic-Barrie S., O'Connor C.R., Looney S.W., Pierangeli S.S., and Harris E.N. A retrospective review of 61 patients with antiphospholipid syndrome: analysis of factors influencing recurrent thrombosis. Arch Intern Med 157 (1997) 2101-2108
32. Erkan D., Merrill J.T., Yazici Y., Sammaritano L., Buyon J.P., and Lockshin M.D. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum 44 (2001) 1466-1467
33. Ginsberg J.S., Kowalchuk G., Hirsh J., Brill-Edwards P., and Burrows R. Heparin therapy during pregnancy: risks to the fetus and mother. Arch Intern Med 149 (1989) 2233-2236
34. Lepercq J., Conard J., Borel-Derlon A., et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG 108 (2001) 1134-1140
35. Roberts D., and Schwartz R.S. Clotting and hemorrhage in the placenta-a delicate balance. N Engl J Med 347 (2002) 57-59
36. Brill-Edwards P., Ginsberg J.S., Gent M., et al., Recurrence of Clot in This Pregnancy Study Group. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. N Engl J Med 343 (2000) 1439-1444
37. Sanson B.J., Lensing A.W., Prins M.H., et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 81 (1999) 668-672
38. Pabinger I., Grafenhofer H., Kaider A., et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost 3 (2005) 949-954
39. De Stefano V., Martinelli I., Rossi E., et al. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol 135 (2006) 386-391
40. Pabinger I., Grafenhofer H., Kyrle P.A., et al. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood 100 (2002) 1060-1062
41. Bates S.M., Greer I.A., Hirsh J., and Ginsberg J.S. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 627S-644S
42. James A.H., Brancazio L.R., and Ortel T.L. Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy. Clin Adv Hematol Oncol 3 (2005) 187-197
43. Branch D.W., and Khamashta M.A. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol 101 (2003) 1333-1344
44. Gris J.C., Mercier E., Quere I., Lavigne-Lissalde G., Cochery-Nouvellon E., Hoffet M., et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 103 (2004) 3695-3699
45. American College of Obstetricians and Gynecologists. Thromboembolism in pregnancy. ACOG Practice Bulletin No. 19 (2000), ACOG, Washington, DC
46. Lockwood C.J. Inherited thrombophilias in pregnant patients: detection and treatment paradigm. Obstet Gynecol 99 (2002) 333-341
47. Moore K.L. Organogenetic period: The fourth to eighth weeks. The Developing Human: Clinically Oriented Embryology. 6th ed. (1998), WB Saunders Company, Philadelphia 83-106
48. Naimi T.S., Lipscomb L.E., Brewer R.D., and Gilbert B.C. Binge drinking in the preconception period and the risk of unintended pregnancy: implications for women and their children. Pediatrics 111 (2003) 1136-1141
49. Iturbe-Alessio I., Fonseca M.C., Mutchinik O., Santos M.A., Zajarias A., and Salazar E. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med 315 (1986) 1390-1393
50. Sadler L., McCowan L., White H., Stewart A., Bracken M., and North R. Pregnancy outcomes and cardiac complications in women with mechanical, bioprosthetic and homograft valves. BJOG 107 (2000) 245-253
51. Chan W.S., Anand S., and Ginsberg J.S. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 160 (2000) 191-196
52. Nassar A.H., Hobeika E.M., Abd Essamad H.M., Taher A., Khalil A.M., and Usta I.M. Pregnancy outcome in women with prosthetic heart valves. Am J Obstet Gynecol 191 (2004) 1009-1013
53. Blickstein D., and Blickstein I. The risk of fetal loss associated with warfarin anticoagulation. Int J Gynaecol Obstet 78 (2002) 221-225
54. Srivastava A.K., Gupta A.K., Singh A.V., and Husain T. Effect of oral anticoagulant during pregnancy with prosthetic heart valve. Asian Cardiovasc Thorac Ann 10 (2002) 306-309
55. Meschengieser S.S., Fondevila C.G., Santarelli M.T., and Lazzari M.A. Anticoagulation in pregnant women with mechanical heart valve prostheses. Heart 82 (1999) 23-26
56. Chen W.W., Chan C.S., Lee P.K., Wang R.Y., and Wong V.C. Pregnancy in patients with prosthetic heart valves: an experience with 45 pregnancies. Q J Med 51 (1982) 358-365
57. Cotrufo M., De Feo M., De Santo L.S., et al. Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol 99 (2002) 35-40
58. Wesseling J., Van Driel D., Heymans H.S., et al. Coumarins during pregnancy: long-term effects on growth and development of school-age children. Thromb Haemost 85 (2001) 609-613
59. Harenberg J., Schneider D., Heilmann L., and Wolf H. Lack of anti-factor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women. Haemostasis 23 (1993) 314-320
60. Schneider D., Heilmann L., and Harenberg J. Placental transfer of low-molecular weight heparin. [in German]. Geburtshilfe Frauenheilkd 55 (1995) 93-98
61. Dahlman T.C., Sjoberg H.E., and Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol 170 (1994) 1315-1320
62. Barbour L.A., Kick S.D., Steiner J.F., et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 170 (1994) 862-869
63. Casele H., Haney E.I., James A., Rosene-Montella K., and Carson M. Bone density changes in women who receive thromboprophylaxis in pregnancy. Am J Obstet Gynecol 195 (2006) 1109-1113
64. Dahlman T.C. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 168 (1993) 1265-1270
65. Fausett M.B., Vogtlander M., Lee R.M., et al. Heparin-induced thrombocytopenia is rare in pregnancy. Am J Obstet Gynecol 185 (2001) 148-152
66. Carlin A.J., Farquharson R.G., Quenby S.M., Topping J., and Fraser W.D. Prospective observational study of bone mineral density during pregnancy: low molecular weight heparin versus control. Hum Reprod 19 (2004) 1211-1214
67. Casele H., and Haney E. Bruising in women undergoing thromboprophylaxis in pregnancy. [abstract]. Am J Obstet Gynecol 193 (2006) S81
68. Matziolis G., Perka C., Disch A., and Zippel H. Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts. Calcif Tissue Int 73 (2003) 370-379
69. Lagrange F., Brun J.L., Vergnes M.C., et al. Fondaparinux sodium does not cross the placental barrier: study using the in-vitro human dually perfused cotyledon model. Clin Pharmacokinet 41 (2002) 47-49
70. Dempfle C.E. Minor transplacental passage of fondaparinux in vivo. N Engl J Med 350 (2004) 1914-1915
71. Girardi G., Redecha P., and Salmon J.E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 10 (2004) 1222-1226
72. Mazzolai L., Hohlfeld P., Spertini F., Hayoz D., Schapira M., and Duchosal M.A. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood 108 (2006) 1569-1570
73. Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., and Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 204S-233S
74. Stewart J.A., Hamilton P.J., and Murdoch A.P. Thromboembolic disease associated with ovarian stimulation and assisted conception techniques. Hum Reprod 12 (1997) 2167-2173
75. Warkentin T.E., Levine M.N., Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332 (1995) 1330-1335
76. McCrae K.R., Bussel J.B., Mannucci P.M., Remuzzi G., and Cines D.B. Platelets: an update on diagnosis and management of thrombocytopenic disorders. Hematology (Am Soc Hematol Educ Program) 282 (2001) 305
77. Macchi L., Sarfati R., Guicheteau M., et al. Thromboembolic prophylaxis with danaparoid (Orgaran) in a high-thrombosis-risk pregnant woman with a history of heparin-induced thrombocytopenia (HIT) and Widal's disease. Clin Appl Thromb Hemost 6 (2000) 187-189
78. Woo Y.L., Allard S., Cohen H., Letsky E., and de Swiet M. Danaparoid thromboprophylaxis in pregnant women with heparin-induced thrombocytopenia. BJOG 109 (2002) 466-468
79. Lindhoff-Last E., and Bauersachs R. Heparin-induced thrombocytopenia-alternative anticoagulation in pregnancy and lactation. Semin Thromb Hemost 28 (2002) 439-446
80. Gill J., and Kovacs M.J. Successful use of danaparoid in treatment of heparin-induced thrombocytopenia during twin pregnancy. Obstet Gynecol 90 (1997) 648-650
81. Huhle G., Geberth M., Hoffmann U., Heene D.L., and Harenberg J. Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin. Gynecol Obstet Invest 49 (2000) 67-69
82. Aijaz A., Nelson J., and Naseer N. Management of heparin allergy in pregnancy. Am J Hematol 67 (2001) 268-269
83. Wijesiriwardana A., Lees D.A., and Lush C. Fondaparinux as anticoagulant in a pregnant woman with heparin allergy. Blood Coagul Fibrinolysis 17 (2006) 147-149
84. Vural K.M., Ozatik M.A., Uncu H., et al. Pregnancy after mechanical mitral valve replacement. J Heart Valve Dis 12 (2003) 370-376
85. Orme M.L., Lewis P.J., de Swiet M., et al. May mothers given warfarin breast-feed their infants?. BMJ 1 (1977) 1564-1565
86. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 108 (2001) 776-789
87. Flessa H.C., Kapstrom A.B., Glueck H.I., and Will J.J. Placental transport of heparin. Am J Obstet Gynecol 93 (1965) 570-573
88. Dimitrakakis C., Papageorgiou P., Papageorgiou I., Antzaklis A., Sakarelou N., and Michalas S. Absence of transplacental passage of the low molecular weight heparin enoxaparin. Haemostasis 30 (2000) 243-248
89. Melissari E., Parker C.J., Wilson N.V., Monte G., Kanthou C., Pemberton K.D., et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost 68 (1992) 652-656
90. Taylor A.A. Successful use of heparinoids in a pregnancy complicated by allergy to heparin. BJOG 108 (2001) 1011-1012
91. de Saint-Blanquat L., Simon L., Toubas M.F., and Hamza J. Treatment with danaparoid during pregnancy for a woman with a cutenous allergy to low-molecular-weight heparin. [in French]. Ann Fr Anesth Reanim 19 (2000) 751-754
92. Myers B., Westby J., and Strong J. Prophylactic use of danaparoid in high-risk pregnancy with heparin-induced thrombocytopaenia-positive skin reaction. Blood Coagul Fibrinolysis 14 (2003) 485-487
93. Dager W.E., and White R.H. Treatment of heparin-induced thrombocytopenia. Ann Pharmacother 36 (2002) 489-503
94. Markwardt F., Fink G., Kaiser B., Klocking H.P., Nowak G., Richter M., et al. Pharmacological survey of recombinant hirudin. Pharmazie 43 (1988) 202-207
95. Lindhoff-Last E., Willeke A., Thalhammer C., Nowak G., and Bauersachs R. Hirudin treatment in a breastfeeding woman. Lancet 355 (2000) 467-468
96. Parody R., Oliver A., Souto J.C., and Fontcuberta J. Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica 88 (2003) 147-148
97. Lagrange F., Vergnes C., Brun J.L., et al. Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro. Thromb Haemost 87 (2002) 831-835
98. Rowan J.A., McCowan L.M., Raudkivi P.J., and North R.A. Enoxaparin treatment in women with mechanical heart valves during pregnancy. Am J Obstet Gynecol 185 (2001) 633-637
99. Duley L., Henderson-Smart D., Knight M., and King J. Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. BMJ 322 (2001) 329-333
100. Coomarasamy A., Honest H., Papaioannou S., Gee H., and Khan K.S. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol 101 (2003) 1319-1332
101. Bailey D.N., Weibert R.T., Naylor A.J., and Shaw R.F. A study of salicylate and caffeine excretion in the breast milk of two nursing mothers. J Anal Toxicol 6 (1982) 64-68
102. Findlay J.W., DeAngelis R.L., Kearney M.F., Welch R.M., and Findlay J.M. Analgesic drugs in breast milk and plasma. Clin Pharmacol Ther 29 (1981) 625-633
103. Kierkegaard A. Side and site of deep vein thrombosis in women using oral contraceptives. Acta Obstet Gynecol Scand 64 (1985) 399-402
104. Kierkegaard A. Deep vein thrombosis and the oestrogen content in oral contraceptives: an epidemiological analysis. Contraception 31 (1985) 29-41
105. Cockett F.B., and Thomas M.L. The iliac compression syndrome. Br J Surg 52 (1965) 816-821
106. Ginsberg J.S., Brill-Edwards P., Burrows R.F., et al. Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost 67 (1992) 519-520
107. Goldhaber S.Z., and Tapson V.F. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 93 (2004) 259-262
108. Bates S.M., and Ginsberg J.S. How we manage venous thromboembolism during pregnancy. Blood 100 (2002) 3470-3478
109. Schafer A.I., Levine M.N., Konkle B.A., and Kearon C. Thrombotic disorders: diagnosis and treatment. Hematology (Am Soc Hematol Educ Program) X (2003) 520-539
110. Barbour L.A., Oja J.L., and Schultz L.K. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol 191 (2004) 1024-1029
111. Casele H.L., Laifer S.A., Woelkers D.A., and Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 181 (1999) 1113-1117
112. Blomback M., Bremme K., Hellgren M., and Lindberg H. A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. Blood Coagul Fibrinolysis 9 (1998) 343-350
113. Brancazio L.R., Roperti K.A., Stierer R., and Laifer S.A. Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. Am J Obstet Gynecol 173 (1995) 1240-1245
114. Jacobsen A.F., Qvigstad E., and Sandset P.M. Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. BJOG 110 (2003) 139-144
115. Sephton V., Farquharson R.G., Topping J., et al. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. Obstet Gynecol 101 (2003) 1307-1311
116. Smith M.P., Norris L.A., Steer P.J., Savidge G.F., and Bonnar J. Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. Am J Obstet Gynecol 190 (2004) 495-501
117. Turrentine M.A., Braems G., and Ramirez M.M. Use of thrombolytics for the treatment of thromboembolic disease during pregnancy. Obstet Gynecol Surv 50 (1995) 534-541
118. Horlocker T.T. Low molecular weight heparin and neuraxial anesthesia. Thromb Res 101 (2001) 141-154
119. Baker W.H., Mahler D.K., Foldes M.S., et al. Pneumatic compression devices for prophylaxis of deep venous thrombosis (DVT). Am Surg 52 (1986) 371-373